Evidence map›Paper›PMID 40661211›Full record

ReviewRSC advances2025

Molecular imaging using (nano)probes: cutting-edge developments and clinical challenges in diagnostics.

Meisam Samadzadeh, Arezoo Khosravi, Atefeh Zarepour, Ghazaleh Jamalipour Soufi, Ali Hekmatnia, Ali Zarrabi, Siavash Iravani

Abstract readReview
In one paragraph

Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Meisam SamadzadehDepartment of Molecular Biology and Genetics, Faculty of Engineering and Natural Sciences, Istinye University Istanbul 34396 Türkiye.
Arezoo KhosraviDepartment of Genetics and Bioengineering, Faculty of Engineering and Natural Sciences, Istanbul Okan University Istanbul 34959 Türkiye.
Atefeh ZarepourDepartment of Biology, Faculty of Arts and Sciences, Kocaeli University 41001 İzmit Kocaeli Türkiye.
Ghazaleh Jamalipour SoufiRadiology Department, School of Medicine, Isfahan University of Medical Science Isfahan Iran ghazalehsoofi@gmail.com.
Ali HekmatniaRadiology Department, School of Medicine, Isfahan University of Medical Science Isfahan Iran ghazalehsoofi@gmail.com.
Ali ZarrabiDepartment of Biomedical Engineering, Faculty of Engineering and Natural Sciences, Istinye University Istanbul 34396 Türkiye alizarrabi@gmail.com.ORCID https://orcid.org/0000-0003-0391-1769
Siavash IravaniIndependent Researcher W Nazar ST, Boostan Ave Isfahan Iran siavashira@gmail.com.ORCID https://orcid.org/0000-0003-3985-7928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Molecular imaging has emerged as a transformative approach in the field of medical diagnostics, enabling the visualization of biological processes at the molecular and cellular levels. Additionally, the integration of molecular imaging with other imaging modalities such as positron emission tomography (PET), magnetic resonance imaging (MRI), computed tomography (CT), photoacoustic imaging (PAI), and fluorescence imaging (FI) has further broadened the scope of diagnostics. Despite significant advances in probe design, including multifunctional and targeted nanomaterials, their clinical translation remains limited by critical challenges. Key obstacles include nanoprobe stability in physiological environments, nonspecific accumulation in the reticuloendothelial system, potential toxicity, and difficulties in achieving optimal biocompatibility and controlled biodistribution. Moreover, the complexity of nanoprobe synthesis and batch-to-batch variability hinder scalable manufacturing and regulatory approval. The primary goal of this review is to critically analyze the current challenges hindering the clinical translation of molecular imaging nanoprobes in biomedicine. While existing literature extensively covers imaging techniques, this review uniquely emphasizes the persistent obstacles-such as nanoprobe stability, biocompatibility, off-target effects, and limited sensitivity-that impede their effective application. Unlike previous reviews, which tend to focus broadly on advancements, we offer a nuanced perspective by identifying specific barriers and proposing promising strategies to overcome them. We explore how surface modification, novel targeting ligands, and smart responsive systems can enhance nanoprobe performance. Furthermore, the review discusses how addressing these challenges is crucial for accelerating the development of multifunctional nanoprobes capable of simultaneous diagnosis and therapy, ultimately advancing personalized medicine. By highlighting these hurdles and potential solutions, this review aims to provide a comprehensive roadmap for researchers striving to optimize molecular imaging nanoprobes, thereby bridging the gap between laboratory innovation and clinical reality.

Identifiers

PMID40661211
PMCPMC12257482

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.